Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation

Blood (2012) 119 (12): 2956–2959.

https://doi.org/10.1182/blood-2011-09-378398

Published: 2012

Includes: Supplemental data

Journal Articles

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Rachel B. Salit, MD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Frances T. Hakim, PhD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Kelly Bryant, RN, Jennifer Wilder, RN, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Ronald E. Gress, MD, Daniel H. Fowler, MD

Blood (2011) 118 (21): 1937.

https://doi.org/10.1182/blood.V118.21.1937.1937

Published: 2011

Journal Articles

Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.

Brian C Shaffer, MD, Marko Modric, David Liewehr, MS, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, MD, Seth Steinberg, PhD, Frances T Hakim, PhD, Kelly Bryant, Jeanne Odom, Paula Layton, BSN, Rachel B Salit, MD, Christoph Rader, PhD, Ronald E Gress, MD, Daniel H Fowler, MD, Michael R Bishop, MD, Steven Z Pavletic, MD

Blood (2010) 116 (21): 3476.

https://doi.org/10.1182/blood.V116.21.3476.3476

Published: 2010

Journal Articles

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, MD, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 656.

https://doi.org/10.1182/blood.V114.22.656.656

Published: 2009

Journal Articles

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 865.

https://doi.org/10.1182/blood.V114.22.865.865

Published: 2009

Journal Articles

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Saad Jamshed, MD, Daniel Fowler, MD, Sattva Neelapu, MD, Robert M. Dean, MD, Seth M Steinberg, PhD, Jeanne Odom, RN, Kelly Snow, RN, Ronald E Gress, MD, Michael R Bishop, MD

Blood (2008) 112 (11): 4328.

https://doi.org/10.1182/blood.V112.11.4328.4328

Published: 2008

Journal Articles

Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.

Iskra Pusic, MD, John Dickinson, MD, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Niveen Atlam, Sandra Mitchell, RN, NP, Daniele Avila, RN, NP, Michael Krumlauf, RN, Kristin Baird, MD, Steven Pavletic, MD

Blood (2007) 110 (11): 1667.

https://doi.org/10.1182/blood.V110.11.1667.1667

Published: 2007

Journal Articles

Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.

Robert M. Dean, MD, Terry Fry, MD, Crystal Mackall, MD, Seth M. Steinberg, PhD, Frances T. Hakim, PhD, Daniel H. Fowler, MD, Jeanne Odom, RN, Jason Foley, MS, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2007) 110 (11): 1064.

https://doi.org/10.1182/blood.V110.11.1064.1064

Published: 2007

Journal Articles

Safety and Efficacy of Cytotoxic Chemotherapy after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Hematologic Malignancy.

Nancy M. Hardy, MD, Jeanne Odom, RN, Kelly Snow, RN, Robert Dean, MD, Steven Pavletic, MD, Claude Sportes, MD, Ronald Gress, MD, Daniel H. Fowler, MD, Michael R. Bishop, MD

Blood (2006) 108 (11): 5333.

https://doi.org/10.1182/blood.V108.11.5333.5333

Published: 2006

Journal Articles

Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

Nancy M. Hardy, MD, Frances Hakim, PhD, Seth Steinberg, PhD, Michael Krumlauf, Rebecca Babb, Jeanne Odom, Daniel Fowler, MD, Ronald Gress, MD, Michael R. Bishop, MD

Blood (2006) 108 (11): 2871.

https://doi.org/10.1182/blood.V108.11.2871.2871

Published: 2006

Journal Articles

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Robert M. Dean, MD, Daniel Fowler, MD, Wyndham H. Wilson, MD, PhD, Frances Hakim, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Catherine Chow, MD, Claude Sportes, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD, Nancy M. Hardy, MD, Ronald Gress, MD, Michael R. Bishop

Blood (2006) 108 (11): 317.

https://doi.org/10.1182/blood.V108.11.317.317

Published: 2006

Journal Articles

IL-15 Plays a Critical Role in CD8+ T-Cell Recovery after Allogeneic Transplantation.

Frances T. Hakim, PhD, Kenton Allen, BA, Jesse M. Carson, BA, Michael Boyiadzis, MD, Sarfraz A. Memon, MD, Robert Dean, MD, Jeanne Odom, R.N., Alan Wayne, MD, Daniel Fowler, MD, Michael R. Bishop, MD, Ronald E. Gress, MD

Blood (2005) 106 (11): 1414.

https://doi.org/10.1182/blood.V106.11.1414.1414

Published: 2005

Journal Articles

Up-Regulation of NK Cell Activating Receptors Associated with Elevated IL-15 Levels Post-Transplant.

Michael Boyiadzis, MD, Jesse Carson, BA, Kenton Allen, BA, Sarfraz A. Memon, MD, Robert A. Dean, MD, Jeanne Odom, R.N., Michael R. Bishop, MD, Ronald E. Gress, MD, Frances T. Hakim, PhD

Blood (2005) 106 (11): 1417.

https://doi.org/10.1182/blood.V106.11.1417.1417

Published: 2005

Journal Articles

Allograft T Cell Content Influences Early Engraftment after Reduced-Intensity Stem Cell Transplantation (RIST).

Robert M. Dean, MD, Daniel H. Fowler, MD, Nancy M. Hardy, MD, Jeanne Odom, RN, Kathleen Castro, MSN, Michael Krumlauf, RN, Frances T. Hakim, PhD, Claude Sportes, MD, Ronald E. Gress, MD, Michael R. Bishop

Blood (2005) 106 (11): 3662.

https://doi.org/10.1182/blood.V106.11.3662.3662

Published: 2005

Journal Articles

Increased Expression of Activating Receptors on NK Cells in the Post-Transplant Period.

Michael Boyiadzis, MD, Jesse M. Carson, Sarfraz A. Memon, MD, Robert Dean, MD, Kate Castro, RN, Jeanne Odom, RN, Michael R. Bishop, MD, Ronald E. Gress, MD, Frances T. Hakim, PhD

Blood (2004) 104 (11): 1249.

https://doi.org/10.1182/blood.V104.11.1249.1249

Published: 2004

Journal Articles

Comparison of Empiric Versus Prophylactic Administration of Ceftazidime during Neutropenia Associated with Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST).

Kyle M. Donley, Juan C. Gea-Banacloche, MD, Robert M. Dean, MD, Seth M. Steinberg, PhD, Richard W. Childs, MD, Jeanne Odom, RN, Kathleen Castro, RN, Tracey Chinn, RN, Daniel H. Fowler, MD, Michael R. Bishop, MD

Blood (2004) 104 (11): 5100.

https://doi.org/10.1182/blood.V104.11.5100.5100

Published: 2004

Journal Articles

Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.

Michael R. Bishop, MD, Robert M. Dean, MD, Wyndham H. Wilson, MD, PhD, Jeanne Odom, RN, Seth Steinberg, PhD, Michael Krumlauf, RN, Claude Kasten-Sportes, MD, Steven Z. Pavletic, MD, Kathleen Castro, RN, Tracey Chinn, RN, Ronald Gress, MD, Daniel H. Fowler, MD

Blood (2004) 104 (11): 1643.

https://doi.org/10.1182/blood.V104.11.1643.1643

Published: 2004

Journal Articles

Immunoablative Chemotherapy before Reduced-Intensity Allogeneic Stem Cell Transplantation: A Strategy to Provide Disease Control and to Enhance Early Graft-Versus-Lymphoma Effects.

Robert M. Dean, MD, Daniel H. Fowler, MD, Frances T. Hakim, PhD, Jeanne Odom, RN, Kathleen Castro, RN, Tracey Chinn, RN, Wyndham H. Wilson, MD, PhD, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2004) 104 (11): 1829.

https://doi.org/10.1182/blood.V104.11.1829.1829

Published: 2004

Journal Articles

Engraftment Syndrome after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Graft-Versus-Host Disease Prophylaxis and T Cell Dose.

Robert M. Dean, MD, Kyle M. Donley, BA, Juan Gea-Banacloche, MD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Michael Krumlauf, RN, Kathleen Castro, RN, Tracey Chinn, RN, Daniel H. Fowler, MD, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2004) 104 (11): 5052.

https://doi.org/10.1182/blood.V104.11.5052.5052

Published: 2004

NARROW

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.

Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.

Safety and Efficacy of Cytotoxic Chemotherapy after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Hematologic Malignancy.

Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

IL-15 Plays a Critical Role in CD8+ T-Cell Recovery after Allogeneic Transplantation.

Up-Regulation of NK Cell Activating Receptors Associated with Elevated IL-15 Levels Post-Transplant.

Allograft T Cell Content Influences Early Engraftment after Reduced-Intensity Stem Cell Transplantation (RIST).

Increased Expression of Activating Receptors on NK Cells in the Post-Transplant Period.

Comparison of Empiric Versus Prophylactic Administration of Ceftazidime during Neutropenia Associated with Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST).

Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.

Immunoablative Chemotherapy before Reduced-Intensity Allogeneic Stem Cell Transplantation: A Strategy to Provide Disease Control and to Enhance Early Graft-Versus-Lymphoma Effects.

Engraftment Syndrome after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Graft-Versus-Host Disease Prophylaxis and T Cell Dose.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only